Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Alberta

$25,000.00

Controlling Salmonella in Poultry

FY 2015-16

Summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. has developed a novel antibody-based therapeutic strategy that could prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and tested for their efficacy using in vitro cell culture methods. The next step requires testing their efficacy in vivo, in pre-harvest chicken flocks. It is imperative to demonstrate that these antibodies, when administered at therapeutic levels in a preventative fashion are capable of eliminating Salmonella, yet have no adverse effects on host physiology or on members of the normal flora. This work capitalizes on the Willing laboratory's expertise in areas of Salmonella pathogenesis and animal physiology. This project proposes to address several critical questions that are essential to the development of NovoBind's anti-Salmonella based therapeutic for livestock: (1) Identify whether NovoBind's antibody-based therapeutic reduces local and systemic Salmonella burdens in poultry, (2) Determine the most effective antibody dose required to limit Salmonella colonization in poultry, (3) Sample the poultry gastrointestinal microbiome to assess the impact of the antibody-based therapy on resident members of the chicken normal flora. The development of a Salmonella-selective, antibody-based therapeutic that has minimal effects on host physiology and normal flora would benefit Canadians and worldwide populations by eliminating a source of antibiotics in the food chain, reducing human infection, illness, loss of life and the costs of treatment.
Program
Engage Grants Program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
484606-2015
Name nom
Willing, Benjamin
Department département
Agricultural, Food and Nutritional Science
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5201
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Bacteriology
Research subject fr
Bactériologie
Partie
1
Nb partie
1
Application title
Controlling Salmonella in Poultry
Keyword
NSERC
Application summary
Salmonella infections represent a significant public health concern and disease burden. Significant sources of infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control of Salmonella infections in poultry products is one means to reduce human infections. While advances have been made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressure on commercial growers to prevent and/or eliminate these pathogens in pre-harvest production facilities. NovoBind Livestock Therapeutics Inc. has developed a novel antibody-based therapeutic strategy that could prevent and/or eliminate Salmonella pathogens in pre-harvest poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and tested for their efficacy using in vitro cell culture methods. The next step requires testing their efficacy in vivo, in pre-harvest chicken flocks. It is imperative to demonstrate that these antibodies, when administered at therapeutic levels in a preventative fashion are capable of eliminating Salmonella, yet have no adverse effects on host physiology or on members of the normal flora. This work capitalizes on the Willing laboratory's expertise in areas of Salmonella pathogenesis and animal physiology. This project proposes to address several critical questions that are essential to the development of NovoBind's anti-Salmonella based therapeutic for livestock: (1) Identify whether NovoBind's antibody-based therapeutic reduces local and systemic Salmonella burdens in poultry, (2) Determine the most effective antibody dose required to limit Salmonella colonization in poultry, (3) Sample the poultry gastrointestinal microbiome to assess the impact of the antibody-based therapy on resident members of the chicken normal flora. The development of a Salmonella-selective, antibody-based therapeutic that has minimal effects on host physiology and normal flora would benefit Canadians and worldwide populations by eliminating a source of antibiotics in the food chain, reducing human infection, illness, loss of life and the costs of treatment.